Skip to main
EW
EW logo

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 32%
Hold 26%
Sell 5%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated robust growth in its transcatheter aortic valve replacement (TAVR) segment, with revenue increasing by 10.6% year-over-year, leading to an upward revision of its 2025 growth guidance to 7-8%. The company has also shown impressive performance in its transcatheter mitral and tricuspid valve technologies (TMTT), reporting a remarkable year-over-year growth of 53.2%, driven by strong demand for products like PASCAL and EVOQUE. With confidence in sustaining revenue growth above 10% through 2026 and an increased EPS outlook for FY25, Edwards Lifesciences positions itself favorably for continued success in the evolving medical device market.

Bears say

Key risks contributing to a negative outlook on Edwards Lifesciences's stock include uncertainties surrounding the growth trajectory of the transcatheter aortic valve replacement (TAVR) market and the potential for a smaller total addressable market than currently expected. Additionally, delays in product innovations within the minimally invasive tricuspid and mitral valve segments may hinder the company's sales growth, while emerging competition could pressure market share and pricing. Finally, a challenging global regulatory and reimbursement landscape poses further risks by potentially delaying technology adoption and impacting revenue growth forecasts.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 32% recommend Buy, 26% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.